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Ewing sarcoma (EwS) is associated with poor prog-
nosis despite current multimodal therapy. Targeting
of EWS-FLI1, the fusion protein responsible for its
pathogenesis, and its principal downstream targets
has not yet produced satisfactory therapeutic op-
tions, fueling the search for alternative approaches.
Here, we show that the oncofetal RNA-binding pro-
tein LIN28B regulates the stability of EWS-FLI1
mRNA in ~10% of EwSs. LIN28B depletion in these
tumors leads to a decrease in the expression of
EWS-FLI1 and its direct transcriptional network,
abrogating EwS cell self-renewal and tumorigenicity.
Moreover, pharmacological inhibition of LIN28B
mimics the effect of LIN28B depletion, suggesting
that LIN28B sustains the emergence of a subset of
EwS in which it also serves as an effective therapeu-
tic target.INTRODUCTION
Ewing sarcoma (EwS) is the second most common bone malig-
nancy in children and young adults. Its distinguishing biologicalCell R
This is an open access article undfeature is a unique set of reciprocal chromosomal translocations
that generate fusions between EWS and one of several genes
encoding ETS family transcription factors, themost common be-
ing FLI1 (Riggi and Stamenkovic, 2007). The EWS-FLI1 fusion
protein underlies EwS pathogenesis and behaves as an aberrant
transcription factor that can induce both transcriptional activa-
tion and repression. Upon binding to GGAA repeat elements,
EWS-FLI1 induces chromatin relaxation and the recruitment of
chromatin-remodeling enzymes to activate de novo enhancers
at genomic regions that are normally devoid of any regulatory
function in other cell types (Boulay et al., 2017; Riggi et al.,
2014; Tomazou et al., 2015). In contrast, by displacing more
active wild-type ETS transcription factors from enhancers con-
taining non-repetitive canonical ETS motifs, EWS-FLI1 causes
target gene repression (Riggi et al., 2014). EWS-FLI1 therefore
behaves as an oncogenic pioneer factor that can reprogram
the regulatory and transcriptional features of permissive primary
cells, leading to their malignant transformation.
EwS has a strong tendency toward relapse and dissemination.
Recurring and metastatic disease respond poorly even to the
most aggressive forms of multimodal therapy that are available
and are associated with a high mortality rate (Pishas and Less-
nick, 2016). Although the search for effective therapeutic strate-
gies continues to be intense, with some potentially promising
leads (Cornaz-Buros et al., 2014; De Vito et al., 2012; Engert
et al., 2015; Erkizan et al., 2009; Vormoor and Curtin, 2014),eports 30, 4567–4583, March 31, 2020 ª 2020 The Authors. 4567
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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few options are available when the standard first-line combina-
tion of surgery and cytotoxic drugs fails. The unstructured
features of EWS-FLI1 hinder its direct targeting (Dunker and
Uversky, 2010), and therapeutically accessible regulators and
downstream effectors of EWS-FLI1 that are vital to EwS growth
have thus far been elusive. One relatively unexplored avenue is
the search for factors that may complement or synergize with
the oncogenic function of EWS-FLI1, and whose targeting may
indirectly blunt EwS aggressiveness and improve patient sur-
vival. To identify such putative factors, we addressed the effects
on patient survival of the top 100 genes observed to affect EwS
cell growth in a recently published whole-genome CRISPR
screen (Aguirre et al., 2016). Among the top candidates identified
by this combinatorial approach, we found the gene that encodes
the oncofetal RNA-binding protein (RBP) LIN28B.
Expression of the LIN28 paralogs (LIN28A and LIN28B) occurs
during normal embryogenesis, at which time they control the bal-
ance between pluripotency and differentiation and regulate the
transition from early to late embryonic development (Shinoda
et al., 2013; Zhang et al., 2016). By inhibiting let-7 microRNA
(miRNA) family biogenesis, LIN28A and LIN28B protect the
expression of let-7 target transcripts, which include numerous
pluripotency-related genes and oncogenes, thereby promoting
normal stem cell maintenance and tumor growth (Madison
et al., 2013, 2015; Mayr and Heinemann, 2013; Thornton and
Gregory, 2012; Viswanathan and Daley, 2010). However,
LIN28A and LIN28B also exert let-7-independent regulatory
functions by binding to and influencing the translation of a
wide repertoire of mRNAs (Balzeau et al., 2017; Viswanathan
and Daley, 2010). LIN28B and, to a lesser extent, LIN28A are
aberrantly expressed in a broad range of adult human malig-
nancies associated with poor prognosis (Chatterji et al., 2018;
Chatterji and Rustgi, 2018), in which they are often confined to
poorly differentiated cell subpopulations that may express can-
cer stem cell (CSC) features (Balzeau et al., 2017; Carmel-Gross
et al., 2016; Viswanathan and Daley, 2010). LIN28B is implicated
in the pathogenesis of several primitive pediatric malignancies,
including Wilms tumor (Urbach et al., 2014), neuroblastoma
(Hennchen et al., 2015; Powers et al., 2016), and primitive
neuro-ectodermal brain tumors (Choi et al., 2016; Picard
et al., 2012).
Based on these observations, we addressed the potential
implication of LIN28B expression in the pathogenesis of EwS.
Using patient-derived EwS spheres from primary LIN28B+
and LIN28B tumors, we show that LIN28B-expressing cells
not only generate tumor growth more rapidly than their
LIN28Bcounterparts but are also dependent on LIN28B
expression to sustain their self-renewal and tumor-initiatingFigure 1. LIN28B Expression Identifies a Subclass of Aggressive EwSs
(A) The waterfall plot depicts Cox survival Z scores for 92 of the 100 genes that sele
Expression of 8 genes was not recorded in the survival dataset (Savola et al., 20
(B) Analytic technique for assessment of RNAi by similarity (ATARiS) score distribu
(C) Scatterplot depicting LIN28B gene expression (red squares, positive; black s
(D) Immunohistochemical (IHC, upper panels) and RNA in situ hybridization (ISH,
images are representative of the 40 primary EwS samples tested (the same tum
observed in 4 of the 40 tumors. The top and bottom images in each panel are LI
See also Figure S1and Tables S1 and S2.properties. We demonstrate that LIN28B directly binds EWS-
FLI1 transcripts, increasing their stability and ensuring themainte-
nance of EWS-FLI1 expression in tumor cells. Consequently,
LIN28B depletion or pharmacological inhibition in primary EwS
cells decreases the expression of both the fusion protein and its
direct target genes, leading to the deconstruction of the onco-
genic program and the progressive loss of tumorigenic potential
in vitro and in vivo. Our observations identify anEwSsubsetwhose
dependence on LIN28B provides a unique opportunity to apply a
pharmacological approach toward disrupting its otherwise un-
druggable oncogenic driving force.
RESULTS
LIN28B Expression Identifies a Subset of EwS
To identify candidate factors whose function may influence EwS
evolution and prognosis, we correlated survival in a cohort of 44
EwS patients (Savola et al., 2011) with the expression of the top
100 genes observed to affect EwS cell growth in a recent whole-
genome CRISPR library screen of 33 cancer cell lines (Aguirre
et al., 2016) (Table S1). In terms of prognostic relevance,
LIN28B ranked second only to RNF216, which encodes a
RING finger protein involved in the regulation of the nuclear fac-
tor kB (NF-kB) pathway (Chuang and Ulevitch, 2004; Nakhaei
et al., 2009), known to promote EwS cell survival (Javelaud
et al., 2000) (Figure 1A). Whereas LIN28B underlies the emer-
gence and evolution of several primitive pediatric malignancies,
its role in EwS is unknown, prompting us to interrogate its puta-
tive implication in EwS pathogenesis. Patients with tumors
expressing LIN28B (n = 3) had the poorest prognosis within the
cohort, with amedian survival of <2 years, whereas the evolution
of patients with tumors lacking LIN28B was less severe
and included multi-year survivors (n = 41; Figure S1A). Interroga-
tion of the Cancer Cell Line Encyclopedia database (CCLE,
Broad Institute; https://portals.broadinstitute.org/ccle) (Barre-
tina et al., 2012) revealed that 3 of the 9 EwS cell lines used in
the CRISPR-Cas9 screen (CADOES1, TC32, and MHHES1;
data not shown) did not express LIN28B and were consequently
unaffected by its targeting by gene editing (Figure 1B). These ob-
servations suggest that LIN28B plays a functional role only in a
subset of EwS.
We next assessed the frequency of LIN28B+ EwS in other da-
tasets. Analysis of publicly available gene expression datasets of
primary EwS revealed that in a cohort of 65 patients, 6 bore
LIN28B+ tumors (Figure 1C) (Brohl et al., 2014). Furthermore, 3
primary EwSwere LIN28B+ in amicroarray dataset of 44 patients
(Figure S1A), and assessment of LIN28B expression in our
cohort of 40 primary EwSs using immunohistochemistry (IHC)ctively affect EwS cell line growth in the Achilles database (Aguirre et al., 2016).
11).
tions for cell lines that have low (<5) and high (R5) expression levels for LIN28B.
quares, negative) across a cohort of 65 primary EwSs (Brohl et al., 2014).
lower panels) assessment of LIN28B expression in primary EwS. The selected
or samples are shown in the IHC and ISH panels). Expression of LIN28B was
N28B+ and LIN28B, respectively.
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Figure 2. Primary LIN28B+ and LIN28B EwS Cells Display Different Growth Kinetics In Vitro and In Vivo
(A) qRT-PCR and western blot analyses of LIN28B expression in 4 primary EwS cell cultures (EwS1–EwS4) analyzed. Asterisks represent values that were set to
0 based on late amplification (means ± SEMs, n = 3 technical replicates).
(B) LIN28B+ tumors (EwS1 and EwS2) display reduced expression levels of let-7 family members compared to their LIN28B counterparts, as assessed by qRT-
PCR analysis. Mean values ± SEMs of 3 technical replicates are shown. The statistical analysis was performed by 2-way ANOVA.
(legend continued on next page)
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and in situ hybridization (ISH) identified 4 LIN28B+ tumors (Fig-
ure 1D; data not shown). Examination of these 4 tumors revealed
that LIN28B expression was uniform and not confined to cell
subpopulations, as is often the case in adult malignancies.
Furthermore, there was no gradation of expression among the
tumors, which scored either strongly positive or negative. The
sum of primary LIN28B+ tumors in these 3 datasets amounted
to 13 from a total of 149 (8.7%).
The recent association between STAG2 and TP53 mutations
and poor clinical outcome in EwS patients (Brohl et al., 2014;
Crompton et al., 2014; Tirode et al., 2014) prompted us to
exclude a possible correlation between these mutations and
LIN28B expression. Analysis of publicly available whole-
exome and transcriptome data from primary EwS (Brohl
et al., 2014) failed to reveal a statistically significant correlation
between STAG2/TP53 mutations and LIN28B expression
(Table S2). LIN28B expression therefore appears to be a
marker of a subset of EwS whose biological properties war-
rant assessment.
Primary LIN28B+ and LIN28B EwS Cells Have Different
Growth Kinetics In Vitro and In Vivo
To address the effect of LIN28B on the behavior of EwS, we
generated patient-derived spheroid cultures from 2 LIN28B+
and 2 LIN28B EwS removed at surgery (EwS1–EwS4; Table
S3). The 2 primary cultures derived from LIN28B+ tumors
(EwS1 and EwS2) displayed robust LIN28B mRNA and protein
expression, whereas neither LIN28B transcripts nor proteins
were detectable in their LIN28B tumor-derived counterparts
(EwS3 and EwS4; Figure 2A). LIN28A was undetectable in any
of our samples, excluding the possibility that it may substitute
for its paralog in LIN28B cells (Figure S1C). Consistent with
the inhibitory effect of LIN28B on let-7 biogenesis, EwS1 and
EwS2 displayed lower levels of mature let-7 than EwS3 and
particularly EwS4 (Figures 2B andS1D), which bore a remarkably
high expression of let-7 family members.
We then asked whether EwS cell behavior in vitro and in vivo
correlates with LIN28B expression. EwS1 and EwS2 proliferated
more rapidly, as assessed by MTS assays in vitro, with a roughly
2-fold shorter doubling time than that of EwS3 and EwS4 (Fig-
ure 2C). Following injection of 1 3 104 cells from dissociated
spheres beneath the kidney capsule of NSG mice, EwS1 and
EwS2 cells produced tumors after 6–8 weeks, whereas the me-
dian duration required for EwS3 and EwS4 tumor engraftment
was 12 and 20 weeks, respectively (Figure 2D). EwS1 and
EwS2 sphere-derived tumors maintained LIN28B expression,
whereas tumors formed by EwS3 and EwS4 spheres remained
LIN28B (Figure 2E), recapitulating the original primary tumor
phenotype. LIN28B expression therefore correlates with rapid
EwS cell division and tumor initiation.(C) Growth curves of the 4 spherogenic EwS cultures in vitro as assessed by MT
normalized to time point 0 (mean ± SD). Two-way ANOVA was used for statistic
(D) Survival curves of NSGmice injected with 13 104 EwS sphere-derived cells in
and the Kaplan-Meyer test was used for statistical analysis.
(E) Immunohistochemical assessment of LIN28B expression in the 4 spherogeni
NSG mice in (D) (lower panels).
***p% 0.001; ****p% 0.0001. See also Figure S1 and Table S3.LIN28B Is Required for LIN28B+ EwS Self-Renewal and
Tumor Initiation
To determine whether LIN28B plays a role in LIN28B+ EwS cell
self-renewal and tumor initiation, we infected EwS1 and EwS2
cells with lentiviral vectors containing either of 2 short hairpin
RNAs (shRNAs), shRNA1 and shRNA2, whose sequences
target the protein coding region and the 30 UTR of LIN28B
mRNA, respectively. Expression of either shRNA resulted in
comparable LIN28B depletion (Figure 3A, left panel, and Fig-
ure 3B) and the corresponding increase in let-7 maturation
(Figure 3A, middle and right panels, and Figures S2A and
S2B). LIN28B depletion virtually abolished sphere formation
by EwS1 and EwS2 cells (Figure 3C). Calcein AM staining of
LIN28B-depleted cells revealed a <10% decrease in viability
(Figure 3D; data not shown), indicating that the observed
abrogation of spherogenicity was not due to cell death. Clono-
genic assays revealed a dramatic decrease in sphere forma-
tion from single EwS1 and EwS2 cells depleted of LIN28B
(Figure 3E). Accordingly, 1 3 104 LIN28B-depleted EwS1
and EwS2 cells were unable to form tumors following injection
beneath the kidney capsule of NSG mice (Figure 3F). Three
mice injected with EwS2 cells expressing LIN28B shRNA2
developed tumors, which were found to express LIN28B at
levels superior to those in control tumors (Figure S2C), having
most likely originated from cells that had eluded stable LIN28B
knockdown. These observations suggest that LIN28B is
necessary for the maintenance of self-renewal and tumor initi-
ation by LIN28B+ EwS cells.
To exclude the possibility that the decreases in clonogenic-
ity and tumor initiation observed using shRNAs were due to
off-target effects, we attempted to rescue the LIN28B+
EwS phenotype by expressing a LIN28B construct that
lacks the 30 UTR (LIN28BD3UTR) in cells depleted of endoge-
nous LIN28B. Following LIN28BD3UTR cDNA introduction
into LIN28B+ EwS cells, the endogenous transcript was
depleted using shRNA2. As expected, shRNA2 affected
neither transcript nor protein LIN28B levels in cells expressing
exogenous LIN28BD3UTR (Figures S2D and S2E). Unlike their
counterparts infected with a control vector, cells expressing
LIN28BD3UTR maintained sphere formation despite the pres-
ence of shRNA2, excluding an off-target effect as an
explanation for our initial observations (Figure S2F). To
provide further support for our findings, we depleted LIN28B
using CRISPR-Cas9. The expression of a validated single-
guide RNA (sgRNA) sequence targeting exon 2 of LIN28B
(Powers et al., 2016) in EwS1 cells virtually abrogated
LIN28B mRNA and protein expression (Figures S2G and
S2H) and resulted in a robust reduction in clonogenicity
(Figure S2I), reproducing the phenotype obtained using
shRNAs.S assays over 72 h. Four biological replicas were performed, and values were
al analysis.
to the left subcapsular kidney compartment. Five mice per group were injected,
c EwS cultures (upper panels) and the tumors generated by their injection into
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Exogenous LIN28B Expression Increases Clonogenicity
of and Tumor Initiation by LIN28B EwS Spheres
We next asked whether the introduction of LIN28B into
LIN28B tumor cells might accelerate their growth and tumor
initiation by stably expressing LIN28BDD3UTR in EwS3 cells (Fig-
ure 4A, left panels). As expected, LIN28B expression resulted in
the suppression of let-7 family maturation and the concomitant
induction of the canonical let-7 target gene HMGA2 (Figure 4A,
center and right panels, respectively). In vitro, EwS3 cells ex-
pressing LIN28B rapidly re-formed spheres following dissocia-
tion (Figure 4B) and displayed a 3-fold increase in clonogenicity
compared to control cells (Figure 4C). Injection of LIN28B-ex-
pressing EwS3 cells under the kidney capsule of NSG mice re-
sulted in detectable tumor growth within 8 weeks in 4 of 6 mice,
reminiscent of the behavior of primary LIN28B+ cells (Figure 2D).
The mean tumor volume at 8 weeks was ~3-fold higher than
that of tumors derived from control cells (Figure 4D). Both
LIN28B and HMGA2 were elevated in tumors derived from
LIN28B-expressing EwS3 cells (Figures 4E and 4F), compared
to their empty-vector-infected counterparts. These observa-
tions support the results obtained using LIN28B-depleted cells
and indicate that the expression of LIN28B alone can augment
the self-renewal and tumor-forming capacity of primary EwS
cells.
LIN28B Modulation Affects Expression of EWS-FLI1 and
Its Target Genes
To further explore the properties of LIN28B+ and LIN28B EwS
subtypes and interrogate the mechanism underlying LIN28B+
EwS cell dependence on LIN28B expression for self-renewal
and tumor initiation, we compared the miRNome and transcrip-
tome of primary LIN28B+ and LIN28B EwS cells using miRNA
arrays and RNA sequencing (RNA-seq), respectively. EwS1
and EwS2 cells displayed a similar miRNA expression profile
and the same held true for EwS3 and EwS4 cells. Although
mature let-7 species were downregulated in EwS1 and EwS2
compared to EwS3 and EwS4, consistent with the inhibition of
let-7 maturation by LIN28B, the corresponding miRNA target
genes were not significantly overrepresented among the genes
that were differentially expressed between LIN28B+ and
LIN28B tumors (Figure 5A). Specifically, only 7 predicted let-7
targets were upregulated in LIN28B+ tumors (7.757 expected
by chance, rendering the enrichment p value non-significant),
suggesting that the LIN28B+ EwS phenotype may arise notFigure 3. LIN28B Is Essential for Self-Renewal and Tumorigenic Prope
(A) qRT-PCR assessment of LIN28B transcript (left panel) andmature let-7 (center
targeting shRNAs (sh1 LIN28B and sh2 LIN28B) compared to those in the same c
SEMs of 3 independent experiments are shown. Two-way ANOVA was used for
(B) Western blot analysis of LIN28B protein levels in EwS1 and EwS2 cells upon
(C) Micrographs of EwS1 and EwS2 spherogenic cultures 96 h after lentiviral infe
(D) Fluorescence-activated cell sorting (FACS) analysis of EwS1 sphere viability 9
(E) Clonogenic assay of EwS1 and EwS2 cultures depleted or not depleted of LIN
statistical analysis.
(F) In vivo tumorigenicity assay after the injection of 13 104 control or LIN28B-de
complete abrogation of the tumorigenic potential of EwS1 and EwS2 cells. The b
developed tumors out of the total number of mice used in each experiment. Fish
symbols indicate visible tumors; empty symbols indicate undetectable tumor gro
*p > 0.05; ***p% 0.001; ****p% 0.0001. See also Figure S2.only from the inhibition of let-7 biogenesis but also from the ef-
fects that LIN28B may exert on its direct target transcripts.
LIN28B affects diverse biological processes, including cell
metabolism and proliferation, independent of its let-7-regulatory
function (Balzeau et al., 2017). To gain deeper insight into the
biological effects of LIN28B in EwS, we generated RNA-seq
expression profiles of EwS1 and EwS2 cells depleted of
LIN28B using shRNA2, and performed functional gene set
enrichment analysis (GSEA) pathway analysis. We found a
marked overlap between the list of downregulated genes in
LIN28B-depleted cells andmultiple gene sets related to the tran-
scriptional function of EWS-FLI1 in EwS (Figure 5B, upper left
panel, and Figure S3A). The top-scoring gene set identified by
this approach was Riggi_Ewing_Sarcoma_Progenitor_Up,
which contains the list of genes induced by EWS-FLI1 in human
pediatric mesenchymal stem cells (hpMSCs) (Riggi et al., 2010).
Direct comparison of this gene set to the genes repressed by
LIN28Bdepletion revealed a highly significant overlap in both pri-
mary cell cultures (EwS1 p = 4.83 1016, EwS2 p = 3.43 1037;
Figure 5B, lower left panel). A set of 32 genes found to be com-
mon to the 2 primary cell cultures and the GSEA gene set
included numerous known EWS-FLI1 targets (Figure 5B, right
panel), suggesting that LIN28B may regulate EWS-FLI1 target
gene expression or, more likely, the expression and function of
EWS-FLI1 itself.
To address the latter possibility, we depleted EwS1 and EwS2
cells of EWS-FLI1 using a validated shRNA sequence (De Vito
et al., 2011) and conducted RNA-seq analysis on these cells
and their corresponding control counterparts infected with an
shRNA sequence targeting GFP mRNA. Comparison of RNA-
seq data from EwS1and EwS2 cells depleted of either LIN28B
or EWS-FLI1 revealed a striking overlap between the two
expression datasets (p value for common downregulated genes
p = 8.6 3 1068 and 1.4 3 10183 for EwS1 and EwS2, respec-
tively; Figures 5C and S3B). We then compared the RNA-seq
profiles of LIN28B-depleted EwS1 and EwS2 cells with a curated
list of 111 EWS-FLI1-activated genes identified by combining the
changes in gene expression observed upon EWS-FLI1 knock
down in 2 EwS cell lines (A673 and SK-N-MC) and upon the len-
tiviral introduction of exogenous EWS-FLI1 into hpMSCs (Table
S4) (Boulay et al., 2018). Of the 111 genes, only 99 were ex-
pressed in our RNA-seq samples and were used in the compar-
ative analysis. Once again, we found a highly significant overlap
for upregulated genes between these datasets from bothrties of LIN28B+ EwS Cells
panel and right panels) levels in EwS1 and EwS2 cells transduced with LIN28B-
ells transduced with GFP-targeting shRNA controls (sh CTRL). Mean values ±
statistical analysis.
shRNA-mediated LIN28B depletion in (A).
ction with either control or LIN28B-targeting shRNAs.
6 h post-transduction with either control or LIN28B-targeting shRNA vectors.
28B (means ± SDs, n = 3 technical replicates). Two-way ANOVA was used for
pleted EwS1 and EwS2 cells. The loss of LIN28B expression results in virtually
ar indicates the mean tumor volume and n indicates the number of mice that
er’s exact test was used for the statistical analysis of tumor counts only. Full
wth.
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Figure 4. LIN28B Expression Increases
LIN28B EwS Cell Self-Renewal and Tumor-
igenicity
(A) Left panel: qRT-PCR (top) and western blot
(bottom) analyses of LIN28B expression in EwS3
spheres transduced with an LIN28B-expressing
vector (LIN28B), compared to spheres transduced
with an empty (CTRL) vector. Mean values ± SEMs
of 3 independent experiments are shown. Center
and right panels: qRT-PCR assessment of mature
let-7a, b, and f (center) and HMGA2 (right) tran-
script levels in LIN28B-expressing EwS3 spheres
compared to their empty-vector-infected coun-
terparts. The means ± SEMs of 3 independent
experiments are shown.
(B) Micrographs of EwS3 cultures 96 h after
dissociation, showing a marked increase in the
spherogenic ability of cells transduced with
LIN28B.
(C) Clonogenic assays of LIN28B-expressing
EwS3 cells compared to their empty-vector-in-
fected counterparts (CTRL, means ± SDs).
(D) Injection of 1 3 104 EwS3 cells into NSG mice
reveals increased tumor initiation by EwS3 cells
expressing exogenous LIN28B. The letter ‘‘n’’ in-
dicates the number of mice that developed tumors
out of the total number of mice used in each
experiment. The bar indicates the mean tumor
volume. The outlier (red square) was not included
in the calculation of the mean.
(E) Average LIN28B (left) and HMGA2 (right) tran-
script levels in tumors from LIN28B-expressing
EwS3 cells, as assessed by qRT-PCR (means ±
SDs, n = 3 technical replicates).
(F) Immunohistochemical analysis of LIN28B pro-
tein expression in control and LIN28B-expressing
EwS3 spheroids, as well as in the tumor xenografts
derived from injection of the corresponding cell
populations into NSG mice. Student’s t test was
used to perform statistical analyses in (A) and (C)
(right panel) and (E) and (G); 2-way ANOVA for
analysis in (C) (left panel).
*p < 0.05; **p < 0.001; ***p % 0.001; ****p %
0.0001.primary EwS cell cultures (p = 4.86 3 1026 and 6.8 3 1051 for
EwS1 and EwS2, respectively; Figures 5C and S3B). The same
held true when the analysis was repeated for downregulated
genes (Figure S3C). These data strongly support a direct func-
tional relation between LIN28B and EWS-FLI1.
To determine the nature of this putative functional relation, we
assessed possible changes in EWS-FLI1 expression upon
LIN28B depletion in our two primary cell cultures. In both
EwS1 and EwS2 cells, the depletion of LIN28B resulted in a
robust decrease in EWS-FLI1 transcript and protein levels (Fig-
ures 5D and S3D). The effect on wild-type (WT) EWS was also4574 Cell Reports 30, 4567–4583, March 31, 2020significant in EwS1 cells, albeit slightly
less marked, whereas it was not signifi-
cant in EwS2 cells (Figure S3D). In
contrast, LIN28B expression increased
upon EWS-FLI1 knockdown (Figure S3E),
excluding a reciprocal positive feedbackloop between the two genes. A comparable decrease in the
expression of a panel of direct EWS-FLI1 target genes in
response to the depletion of either LIN28B or EWS-FLI1 (Fig-
ure 5E, left and center panels) further validated these results.
Similar observations were made upon the depletion of LIN28B
from EwS1 cells using CRISPR-Cas9 (Figure 5E, right panel).
LIN28B Stabilizes EWS-FLI1 Transcripts
To address the possibility that LIN28B may protect EWS-FLI1
transcripts from let-7-mediated silencing, we attempted to over-
express let-7a in EwS1 and EwS2 spheres. However, we were
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Figure 5. LIN28B Regulates EWS-FLI1 Expression in LIN28B+ EwS Cells
(A) Heatmap of Z scores of differentially expressed miRNAs between LIN28B+ and LIN28B EwS cells. The number of discordant predicted targets (down-
regulated in response to upregulated miRNAs and vice versa) and the corresponding enrichment p values are shown at left. White cells correspond to poorly
conserved miRNA families for which no high-confidence target predictions are available in TargetScan.
(B) Top panel: functional GSEA pathway analysis of EwS2 cells depleted of LIN28B using shRNA2. Bottom panel: Venn diagram depicting the overlap among
genes repressed by LIN28B depletion in EwS1 and EwS2 cells and the ‘‘Riggi_Ewing_Sarcoma_Progenitor_Up’’ GSEA gene set (bottom). Right panel: gene
expression heatmap of the 32 shared genes in the Venn diagram.
(C) Venn diagrams illustrating the overlap between genes repressed by LIN28B and EWS-FLI1 depletion in EwS1 and EwS2 cells, as well as part of a curated list of
99 direct EWS-FLI1 target transcripts.
(D) qRT-PCR assessment of EWS-FLI1 and WT EWS expression in EwS1 and EwS2 cells following shRNA-mediated LIN28B depletion. Means ± SEMs of 3
independent experiments are shown.
(legend continued on next page)
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unable to obtain overexpression, most likely because of let-7
toxicity in EwS cells (De Vito et al., 2011). We therefore interro-
gated the TargetScanHuman 7.1 web tool (Agarwal et al.,
2015), but found that EWS-FLI1 mRNA does not contain any
let-7 binding sites. A reasonable assumption then may be that
as an RBP targeting a broad repertoire of mRNAs, LIN28B binds
EWS-FLI1 transcripts and preserves their expression. Consis-
tent with this hypothesis, EWS-FLI1 was enriched in LIN28B
RNA immunoprecipitation (RIP) assays on the lysates of both
EwS1 and EwS2 cells (Figure 6A). WT EWS transcripts were
also enriched in LIN28B RIPs (Figure 6A), whereas FLI1 mRNA
is not expressed in EwS cells. To distinguish between the
possible effects of LIN28B on EWS-FLI1 transcription versus
stability, we assessed EWS-FLI1 and its target gene nascent
mRNA levels in the presence and absence of LIN28B. Whereas
nascent EWS-FLI1 transcripts were unaffected by LIN28B
depletion, all of its selected target gene transcript levels dis-
played a marked decrease (Figure 6B), refuting LIN28B-medi-
ated control of EWS-FLI1 transcription and pointing toward the
regulation of its stability. To further examine this potential mech-
anism of action, actinomycin D (ActD)-mediated blockade of
transcription was conducted in EwS2 cells in the presence and
absence of LIN28B, and EWS-FLI1 transcript levels were
measured by qRT-PCR. Depletion of LIN28B led to the observed
decrease in EWS-FLI1 transcripts, and treatment with ActD re-
sulted in a significant, additional decrease in EWS-FLI1 expres-
sion (Figure 6C, upper panel). To obtain deeper insight into the
effect of LIN28B on EWS-FLI1 stability, we addressed changes
in EWS-FLI1 expression at early time points following ActD
administration in the presence or absence of LIN28B. ActD alone
revealed that the half-life of EWS-FLI1was 5.9 and 5.2 h in EwS1
and EwS2 cells, respectively (Figures 6C and S3F). In the
absence of LIN28B, the EWS-FLI1 transcript half-life was
reduced to 2 h in both primary cultures (Figures 6C and S3F).
In the LIN28B EwS3 cells, the half-life of EWS-FLI1 was 1.7 h,
comparable to that in EwS1 and EwS2 cells depleted of
LIN28B (Figure S3G). These observations support the notion
that by directly binding EWS-FLI1 transcripts, LIN28B protects
them from degradation. Accordingly, the depletion of either
LIN28B or EWS-FLI1 in EwS1 and EwS2 cells produced a com-
parable decrease in their proliferation (Figure S3H).
The demonstration that LIN28B stabilizes EWS-FLI1 mRNAs
suggests that it may boost EWS-FLI1 expression. However,
the expression of EWS-FLI1 and that of its direct target genes
was not higher in LIN28B+ than in LIN28B EwS cells (Fig-
ure S4A), nor did the expression of EWS-FLI1 increase in
EwS3 cells (LIN28B) upon the introduction of LIN28BD3UTR (Fig-
ure S4B). Furthermore, comparison of differentially expressed
genes in EwS1 and EwS2 cells depleted of LIN28B to those in
EwS3 cells overexpressing LIN28B revealed no significant over-
lap (Figure S4C), indicating that exogenous LIN28B expression
in LIN28B EwS cells does not recreate the naturally occurring
LIN28B+ EwS phenotype.(E) Expression of a panel of known direct EWS-FLI1 target genes in EwS1 and Ew
(right panel) LIN28B depletion. shRNA- andCRISPR-Cas9-LIN28B-depleted cells
vector-infected cells, respectively. Means ± SEMs of 3 independent experiments
***p% 0.001; ****p% 0.0001; ns, non-significant. See also Figures S3 and S4 an
4576 Cell Reports 30, 4567–4583, March 31, 2020LIN28B EwS cells may have developed different mecha-
nisms to ensure EWS-FLI1 stability, rendering LIN28B redun-
dant. Full assessment of the effect of LIN28B may therefore
require a cellular environment that is permissive for EWS-FLI1
expression and function but that does not naturally express the
fusion protein. To test this possibility, we engineered primary
hpMSCs to conditionally express EWS-FLI1 cDNA under the
control of a doxycycline-inducible promoter and infected them
with lentiviruses containing LIN28B or an empty control vector.
Expression of EWS-FLI1 was then induced by treating the cells
with doxycycline and the expression level of EWS-FLI1, as well
as that of a panel of its target genes in LIN28B-expressing and
LIN28B hpMSCs, were compared. Using 2 unrelated primary
hpMSC batches, we observed ~3-fold higher EWS-FLI1 expres-
sion in cells expressing LIN28B and an even greater difference in
its expression at the protein level (Figures 6D and S4D). The
augmented EWS-FLI1 expression in LIN28B-expressing
hpMSCs was accompanied by a corresponding increase in the
expression of a selection of its target genes, including AMER2,
SOX2, CCK, NKX2.2, and NGFR (Figures 6D and S4D), ranging
from slightly less than 1.5-fold for NKX2.2 to >10-fold for CCK.
These observations support the LIN28B-mediated stabilization
of EWS-FLI1 transcripts in the appropriate cellular environment.
They also confirm that themechanismofEWS-FLI1maintenance
by LIN28B is let-7 independent, since the EWS-FLI1 expression
construct used in hpMSCs lacks the 30 UTR. These observations
point to a hitherto unrecognized regulatory mechanism of EWS-
FLI1 expression that is exploited by a subclass of EwS.
Treatment with LIN28 Inhibitor 1632 Impairs In Vitro
Clonogenicity and In Vivo Growth of LIN28B+ but Not
LIN28B EwS Cells
The observation that LIN28B stabilizes EWS-FLI1 expression
renders its inhibition a potentially attractive means to treat the
subset of tumors that express LIN28B. Recently, the small mole-
cule 1632 (N-methyl-N-[3-(3-methyl[1,2,4]triazolo[4,3-b]-pyrida-
zin-6-yl)phenyl]acetamide) was shown to block the recognition
of let-7 miRNA precursors by the LIN28 paralogs (Roos et al.,
2016). Because the let-7 miRNA family directly regulates LIN28
expression, we reasoned that the 1632 inhibitor may provide a
pharmacological means to disrupt EWS-FLI1 expression in
LIN28B+ EwS, by the repression of LIN28B itself. Treatment
with the 1632 inhibitor at 2 different concentrations (50 and
250 mM) for different durations (4–7 days) elicited different re-
sponses in LIN28B+ and LIN28B EwS cells. In EwS1 and
EwS2 cells, the compound caused a robust increase in let-7
maturation (Figure 7A, left panel, and Figure S5A; data not
shown) and a corresponding decrease in the expression of the
LIN28B target gene HMGA2 (Figure 7A, right panel). In contrast,
the expression of immature and mature let-7 forms did not un-
dergo a significant change in EwS3 and EwS4 cells in response
to the inhibitor (Figure 7A, left panel; data not shown), and
HMGA2 expression displayed no significant decrease in eitherS2 cells following shRNA- (left and center panels) and CRISPR-Cas9-mediated
were compared toGFP-targeting shRNA andCRISPR-Cas9 control guide RNA
are shown. Two-way ANOVA was used for statistical analysis.
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primary cell culture (Figure 7A, right panel). Consistent with these
observations, functional assays revealed that after 96 h of treat-
ment with the inhibitor at 250 mM, EwS1 and EwS2 cells lost their
ability to re-form spheres following dissociation, whereas sphere
formation by EwS3 and EwS4 remained unaffected irrespective
of the concentration of the compound or treatment duration (Fig-
ures 7B and S5B, upper panel; data not shown). Consistent with
our observations on the effect of LIN28B depletion, survival of
the 4 primary cultures was not significantly affected by the com-
pound (Figure S5B, lower panel). Clonogenic assays using all 4
primary cell cultures pre-treated with the inhibitor for 96 h and
then treated continuously at 250 mM for 2 weeks showed an un-
equivocal decrease in sphere-forming capacity by single EwS1
and EwS2 cells, but no change in EwS3 and EwS4 cell clonoge-
nicity (Figure 7C).
We next sought to determine whether the treatment of
LIN28B+ cells with the 1632 inhibitor results in the expected
decrease in EWS-FLI1 expression, as initially hypothesized. In
response to the compound at 250 mM, both EWS and EWS-
FLI1 protein expression was abolished in EwS1 cells (Fig-
ure S5C). We then performed an RNA-seq analysis on EwS1
spheres that had been cultured in the presence of the inhibitor
for 7 days and compared the resulting gene expression profile
with the ones obtained following LIN28B and EWS-FLI1 deple-
tion. Once again, we observed a statistically significant overlap
between the expression profile of 1632-treated EwS1 cells and
the different datasets (p = 1.32 3 1034, 3.77 3 1051, and
4.92 3 1023 for shLIN28B, shEWS-FLI1, and EWS-FLI1 target
genes, respectively; Figures 7D and S5D). These results were
validated by the assessment of changes in the expression of
LIN28B, EWS-FLI1, and EWS-FLI1 target genes in EwS1 cells
treated with the 1632 inhibitor for 7 days (Figure 7E).
As the 1632 compound has not been tested in vivo, we could
not assess the effect of its continuous infusion on tumors
growing in mice. Nevertheless, to determine whether the
observed effect on clonogenicity is reflected by the inhibition
of tumor growth in vivo, we injected 1 3 104 EwS1 and EwS2
cells under the kidney capsule of NSG mice after 96 h of pre-
treatment with 250 mM of the 1632 inhibitor or DMSO. All of the
mice were sacrificed 8 weeks post-injection, when tumors in
untreatedmice had grown to themaximal size allowed by the an-
imal experimentation ethics commission. Despite the subopti-
mal treatment conditions, we observed a robust decrease inFigure 6. LIN28B Controls EWS-FLI1 Transcript Stability in LIN28B+ Ew
(A) RNA immunoprecipitation assay (RIP). qRT-PCR analysis of EWS-FLI1 and W
noprecipitation (upper panel). The 18S genewas used as an internal control, and re
immunoprecipitates. Student’s t test was used for statistical analysis.
(B) Nascent RNA assay for EWS-FLI1 and EWS-FLI1 target transcripts in the pre
effect on nascent EWS-FLI1 mRNA, whereas it strongly depletes EWS-FLI1 targ
(C) Analysis of transcript levels upon ActD treatment, suggesting that LIN28B re
LIN28B depletion for 36 h, after which 10 mMActD or solvent (equivalent volume o
expression was measured (upper panel). To determine the half-life of EWS-FLI1
presence of ActD (lower panel). EWS-FLI1 transcript half-life, as estimated from
(D) Left panel: expression of EWS-FLI1, LIN28B, and a panel of known direct EWS
pInd EWS-FLI1 and pLIV LIN28B, respectively (mean values ± SDs of 3 techni
Student’s t test was used for statistical analysis. Right panel: western Blot analys
lentiviral vectors and cultured with (+ doxy) or without doxycycline for 8 days.
*p% 0.05, **p% 0.01; ****p% 0.0001. See also Figures S3 and S4.
4578 Cell Reports 30, 4567–4583, March 31, 2020the size of tumors derived from treated EwS1 and EwS2 cells
(Figure 7F). These observations demonstrate the feasibility of
suppressing EWS-FLI1 and its oncogenic effects by targeting
the LIN28B-dependent mechanism that maintains its
expression.
DISCUSSION
Using an unbiased approach to search for factors that associate
with EWS-FLI1 in promoting EwS pathogenesis, we identified
LIN28B as a regulator of EWS-FLI1 expression and function in
a small percentage of EwSs that depend on LIN28B for the
expression and maintenance of their identity. A possible
outcome of this discovery is that EwSs expressing LIN28B
may be sensitive to its inhibition, warranting further investigation
of LIN28B as a therapeutic target in some cases of EwS.
The RBPs LIN28A and LIN28B abrogate the processing of pri-
mary and precursor let-7 family hairpins into mature let-7 miR-
NAs (Mayr and Heinemann, 2013; Thornton and Gregory,
2012; Viswanathan and Daley, 2010) and help maintain normal
development and pluripotency by preventing let-7-induced dif-
ferentiation in mouse embryonic stem cells (Zhang et al.,
2016). Conversely, mature let-7 represses LIN28B translation
as part of a negative feedback loop (Thornton and Gregory,
2012; Zhang et al., 2016). The maintenance of pluripotency
and the protection of numerous oncogenes from let-7-mediated
silencing are thought to be the principal mechanisms by which
LIN28B promotes cancer growth and progression. However,
as our observations suggest, LIN28B may also exert oncogenic
properties by directly binding to mRNA (Mayr and Heinemann,
2013), which is consistent with the notion that themost abundant
class of RNAs bound by LIN28B is protein coding transcripts
(Hafner et al., 2013). A recently identified LIN28B target mRNA
was TLS/FUS, a close relative of EWS, which, similar to EWS,
partners with several genes to generate oncogenic fusion pro-
teins (Wilbert et al., 2012).
The introduction of LIN28B into LIN28B primary EwS cells
conferred increased proliferation and clonogenicity, as well as
accelerated tumor-initiating capacity onto the cells, all of which
are consistent with the effects that LIN28B exerts on diverse tu-
mor cell types (Viswanathan et al., 2009). The mechanisms un-
derlying these effects are most likely a combination of let-7
maturation suppression and modulation of the stability of theS Cells
T EWS transcripts in EwS1 and EwS2 cells following LIN28B protein immu-
sults were compared to non-specific isotype-matched immunoglobulin G (IgG)
sence and absence of LIN28B in EwS1 cells. LIN28B-targeting shRNA has no
et transcripts (means ± SDs of 3 technical replicates).
gulates EWS-FLI1 RNA stability in EwS2 cells. EwS2 cells were subjected to
f DMSO) was added for an additional 24 h, during which LIN28B and EWS-FLI1
, the decay rate was measured by qRT-PCR at 5 time points over 8 h in the
the expression curves, is indicated.
-FLI1 target genes in hpMSC1, infected with pInd EWS-FLI1 or co-infected with
cal replicates). EWS-FLI1 was induced by doxycycline treatment for 8 days.
is of EWS-FLI1 and LIN28B expression in hpMSC1 infected with the indicated
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available repertoire of direct LIN28B target transcripts. However,
exogenous LIN28B affected neither EWS-FLI1 expression nor
that of its target gene repertoire in EwS cells. Thus, the changes
in the behavior of these cells in response to the introduction of
LIN28B were not the result of altered EWS-FLI1 expression or
function but rather the superposition of the respective oncogenic
properties of LIN28B and EWS-FLI1.
In stark contrast was the effect of depleting LIN28B+ EwS cells
of their endogenous LIN28B, which included a dramatic
decrease in EWS-FLI1 expression along with that of its direct
target genes, accompanied by the loss of self-renewal and tumor
initiation. By far the most dominant trait of the transcriptome
change associated with LIN28B depletion was the suppression
of direct EWS-FLI1 target transcripts. Changes related to let-7
maturation and binding of LIN28B to other mRNA targets were
not comparable to those of the EWS-FLI1 target gene repertoire.
From a functional standpoint, depletion of EWS-FLI1 or LIN28B
alone from these cells decreased their proliferation to a similar
degree, despite the fact that LIN28B transcripts increased
more than 2-fold in response to EWS-FLI1 knockdown. LIN28B
therefore appears to provide indispensable support for EWS-
FLI1 expression and function in these cells, and the absence of
let-7 recognition sites in EWS-FLI1 argues that LIN28B itself
bears responsibility for the stability of EWS-FLI1.
The depletion of LIN28B in LIN28B+ EwS cells resulted in a
decrease in EWS-FLI1 transcript half-life to a level in the vicinity
of that observed in LIN28B cells. As EWS-FLI1 expression in
LIN28B cells is sufficient to allow it to fulfill its oncogenic func-
tions, these cells must either possess an alternative mechanism
to ensure EWS-FLI1 stability or lack the putative machinery that
degrades EWS-FLI1 and is countered by LIN28B in LIN28B+
cells. Alternatively, the stability of EWS-FLI1 may be ensured
at the protein level in LIN28B EwS cells. Regardless of the
mechanism, and unlike hpMSCs, LIN28B EwS cells appear to
have established, possibly over time, regulatory mechanisms
of EWS-FLI1 expression that are independent of and unrespon-
sive to LIN28B.
A more fundamental question is why should LIN28B be indis-
pensable for EWS-FLI1 expression in a subset of EwS?One pos-
sibility is that LIN28B provides the permissiveness required for
EWS-FLI1-mediated transformation of the primary cells from
which the LIN28B+ EwS subclass originates. This notion wouldFigure 7. The LIN28 Inhibitor 1632 Acts Selectively on LIN28B+ EwS
Tumorigenic Properties
(A) Left panel: qRT-PCR analysis of mature let7-a, b, and f expression in EwS1 and
250 mM), compared to that in the same cells treated with solvent alone (equivalen
are shown. Right panel: qRT-PCR analysis ofHMGA2 expression in EwS1–EwS4 c
7 (means ± SEMs of 3 technical replicates). Two-way ANOVA was used for stati
(B) Micrographs of EwS1 and EwS4 sphere cultures after 96 h of treatment with
(C) Clonogenic assay on EwS1–EwS4 cells treated with DMSO (CTRL) or 250 mM
(D) Venn diagram showing overlap among 4 gene datasets, including LIN28B knoc
at 7 days (common downregulated genes); and the list of 99 direct EWS-FLI1 ta
(E) qRT-PCRassessment of LIN28B,EWS-FLI1, andWTEWS expression, as well a
7 days of treatment with the 1632 compound compared to that in the same cells tr
3 independent experiments are shown. Two-way ANOVA was used for statistica
(F) In vivo tumorigenicity assay after the injection of 1 3 104 EwS1 (left panel) or
inhibitor or solvent (equivalent volume of DMSO, CTRL). The bar indicates the m
*p% 0.05; ****p% 0.0001; ns, non-significant. See also Figure S5.
4580 Cell Reports 30, 4567–4583, March 31, 2020suggest that LIN28B+ and LIN28B EwSmay have different cells
of origin. In response to LIN28B expression, hpMSCs increase
their proliferation, upregulate EWS-FLI1 target genes, and
augment EWS-FLI1 expression. However, they do not require
LIN28B expression for long-term EWS-FLI1 maintenance (Riggi
et al., 2008). In most malignancies in which LIN28B expression
becomes induced as a consequence of reprogramming linked
to transformation, its expression is heterogeneous and is often
confined to poorly differentiated cells that may display CSC fea-
tures (Balzeau et al., 2017). In contrast, LIN28B+ EwS express
LIN28B in virtually all cells, suggesting that these tumors may
arise from a stem or an early progenitor cell that has not turned
off LIN28B expression. Interrogation of a published expression
array of 33 normal adult tissues, which includes human neural
crest stem cells (NCSCs) and MSCs (GEO accession:
GSE68776), revealed high LIN28B expression in NCSCs and
NC-derived MSCs (NC-MSCs) but low to undetectable expres-
sion in bone marrow MSCs (BM-MSCs) (Figure S4E). All 3 cell
types are permissive for EWS-FLI1 expression (Riggi et al.,
2005, 2008, 2010; von Levetzow et al., 2011), but their permis-
siveness may invoke different mechanisms. Thus, the expres-
sion of EWS-FLI1 in NCSCs and NC-MSCs may require
LIN28B and thereby lead to the development of LIN28B+ EwS,
whereas in BM-MSCs, it may result in LIN28B tumors, which
may rely on alternative mechanisms to ensure EWS-FLI1
stability.
Treatment of EwS cells with the 1632 compound that blocks
LIN28B binding to let-7 precursors and disrupts the LIN28B-
mediated inhibition of let-7 maturation did not affect LIN28B
cell behavior, but it did abrogate LIN28B+ cell self-renewal.
Even limited pre-treatment of LIN28B+ cells before injection
into mice blunted their tumorigenicity, reflecting the extent of
their dependence on LIN28B. Although these effects are consis-
tent with increased let-7 expression, the 1632 inhibitor also
caused a decrease in EWS-FLI1 and its target gene expression,
which are let-7 independent. There are at least two non-mutually
exclusive explanations for this seemingly counterintuitive obser-
vation. As LIN28B mRNA-binding sites have not been exhaus-
tively elucidated (Mayr and Heinemann, 2013), it is possible
that the inhibitor may interfere with LIN28B binding to EWS-
FLI1 transcripts, particularly in view of the discovery that some
LIN28B mRNA consensus binding sites are similar to those ofCells, Leading to a Marked Reduction in Their Self-Renewal and
EwS4 cells, treatedwith increasing concentrations of the 1632 inhibitor (50 and
t volume of DMSO, CTRL). Mean values ± SEMs of 3 independent experiments
ultures treated with 250 mMof the 1632 inhibitor and assessed at days 0, 4, and
stical analysis.
DMSO (CTRL) or 250 mM of the 1632 inhibitor.
of the 1632 inhibitor (means ± SDs of 3 technical replicates).
kdown, EWS-FLI1 knockdown, and treatment with 250 mMof the 1632 inhibitor
rget genes described in Figure 5C.
s that of a panel of known direct EWS-FLI1 target genes in EwS1 cells following
eated with solvent alone for the same period of time. Mean values ± SEMs from
l analysis.
EwS2 (right panel) cells following 96 h of treatment with 250 mM of the 1632
ean value.
let-7 precursors (Hafner et al., 2013;Wilbert et al., 2012). Alterna-
tively, the depletion of LIN28B by increased let-7 maturationmay
result in the progressive loss of EWS-FLI1 expression and
deconstruction of its target gene network. Although it may be
relevant to a minority of patients, the exquisite dependence of
EWS-FLI1 expression on LIN28B function may provide an un-
precedented therapeutic perspective for EwS.STAR+METHODS
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Antibodies
Rabbit polyclonal anti-EWS Bethyl Cat#A300-418A; RRID: AB_420958
Mouse monoclonal anti-Tubulin Millipore Cat#CP06; RRID: AB_2617116
Rabbit polyclonal anti-FLI1 Abcam Cat#ab15289; RRID: AB_301825
Rabbit Anti-Human LIN28B Polyclonal Antibody Proteintech Cat# 16178-1-AP; RRID:AB_2135051
Rabbit Anti-Human LIN28B Polyclonal Antibody Cell Signaling
Technology
Cat# 4196; RRID:AB_2135047
Monoclonal Anti-GAPDH-Peroxidase antibody
produced in mouse
Sigma-Aldrich Cat# G9295; RRID:AB_1078992
Anti-Rabbit IgG (whole molecule)-Peroxidase
antibody produced in goat
Sigma-Aldrich Cat#A0545; RRID:AB_257896
Biological Samples
EwS1-4 This paper See Table S3
hpMSC1-2 This paper See Method Details
Chemicals, Peptides, and Recombinant Proteins
IMDM, GlutaMAX SupplementIMDM Thermofisher Scientific Cat#31980022
DMEM, high glucose, GlutaMAX
Supplement, pyruvate
Thermofisher Scientific Cat#31966021
KnockOut Serum Replacement - Multi-Species Thermofisher Scientific Cat#10828028
FBS Good Forte PAN BIOTECH Cat#P40-49500
Trypsin-EDTA (0.05%), phenol red Thermofisher Scientific Cat#25300062
MEM Non-Essential Amino Acids Solution Thermofisher Scientific Cat#11140035
Penicillin-Streptomycin (10,000 U/mL) Thermofisher Scientific Cat#15140122
EGF Human PROSPEC Protein
specialists
Cat#CYT-217
FGF 2 Human PROSPEC Protein
specialists
Cat#CYT-218
Fugene 6 Promega Cat#E2692
Polybrene Sigma-Aldrich Cat#005557
Puromycin InvivoGen Cat#ant-pr-1
PowerUp SYBR Green Master Mix Applied Biosystems Cat#A25742
Calcein AM cell-permeable-dye Life Technologies Cat#C1430
Lin28 1632 Tocris Bioscience Cat#6068
Dimethyl sulfoxide Sigma-Aldrich Cat#41640
Actinomycin D Sigma-Aldrich Cat#A1410
VectaMount AQ Aqueous Mounting Medium Vector Laboratories Cat#H-5501
M-MLV Reverse Transcriptase Promega Cat#M170B
RNasin Ribonuclease inhibitor Promega Cat#N211B
RPMI 1640 Medium, GlutaMAX Supplement Thermofisher Scientific Cat#61870010
Lin28B RNAscope Probe ACD Cat#596361
dNTP set MP Biomedicals Cat#11NTACG100-CF
Doxycycline hyclate Sigma-Aldrich Cat#D9891
Geneticin Thermofisher Scientific Cat#10131-027
FBS (tetracyclin-free) PAN BIOTECH Cat#P30-3602
Ketasol-100 Dr. E. Graeub AG Cat#668.51
Rompun 2% Provet AG Cat#1315
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
PDGF-BB PeproTech Cat#100-14B
Critical Commercial Assays
miRCURY RNA Isolation Kit - Cell & Plant Exiqon Cat#300110
Click-iT Nascent RNA Capture Kit Life Technologies Cat#10365
NucleoSpin miRNA kit Macherey-Nagel Cat#740971
EZ-Magna RIPTM RNA-Binding Protein
Immunoprecipitation kit
MerckMillipore Cat#PP64B
CellTiter 96 AQueous One Solution Cell
Proliferation Assay
Promega Cat#G3582
Deposited Data
Gene expression data for Ewing sarcoma
spheres generated for this project
This Paper GEO: GSE122632
Gene expression data for primary Ewing sarcomas Savola et al., 2011 GEO: GSE17618
Gene expression data for primary Ewing sarcomas Brohl et al., 2014 https://pob.abcc.ncifcrf.gov/
cgi-bin/JK
Gene sets for functional enrichment analysis Broad Institute Molecular Signatures Database,
RRID:SCR_016863
ATARIS gene scores Aguirre et al., 2016 https://depmap.org/portal/download/
Experimental Models: Cell Lines
Lenti-X 293T Clontech Cat#632180
A-673 ATCC Cat# CRL-1598, RRID:CVCL_0080
Experimental Models: Organisms/Strains
NNOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ The Jackson Laboratory RRID:IMSR_JAX:005557
Oligonucleotides
Random Primers Promega Cat#C118A
Primer sequences for real-time PCR This paper see Table S5
sgRNA targeting Lin28B (exon2):
CACCGCATCGACTGGAATATCCAAG
Powers et al., 2016 N/A
Recombinant DNA
shRNA Lin28B n.1 Broad Institute,
RNAi Consortium
Cat#TRCN0000219859
shRNA Lin28B n.2 Broad Institute,
RNAi Consortium
Cat#TRCN0000122191
shRNA targeting EWS-FLI-1 Tirode et al., 2007 N/A
pInd EWS-FLI1 Boulay et al., 2017 N/A
Software and Algorithms
FlowJo version 9.9.4 FLOWJI, LLC https://www.flowjo.com/
solutions/flowjo/, RRID:SCR_008520
Adobe Illustrator CC 2015 Adobe https://www.adobe.com/products/
illustrator.html, RRID:SCR_010279
GraphPad Prism version 8 GraphPad Software https://www.graphpad.com/,
RRID:SCR_002798
Oligo Carvalho and Irizarry, 2010 Bioconductor, RRID:SCR_006442
Limma Ritchie et al., 2015 Bioconductor, RRID:SCR_006442
R Project for Statistical Computing R Development Core
Team, 2019
R Project for Statistical Computing,
RRID:SCR_001905
RSEM Li and Dewey, 2011 https://github.com/deweylab/RSEM
Other
Ensembl Aken et al., 2017 Ensembl Genome Browser,
RRID:SCR_013367
TargetScan Agarwal et al., 2015 TargetScan, RRID:SCR_010845
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ivan Sta-
menkovic (Ivan.Stamenkovic@chuv.ch). All unique/stable reagents generated in this study are available from the Lead Contact with a
completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Primary tumors and cell lines cultures
Primary EwS and MSC samples from the University Hospital of Lausanne (CHUV) were obtained at surgery with the approval of the
Ethics Committee of the Canton de Vaud (project authorization No. 131/12). For samples received from the Hospital Sant Joan de
De´u (HSJD, Barcelona), written informed consent was obtained from all patients prior to inclusion of their samples in the tumor bio-
bank, following procedures approved by the Ethical Committee for Clinical Research at HSJD (M. 1608-C). All human samples were
anonymized before analysis and were exempted from informed consent in accordance with the law of the Canton de Vaud. Table S3
lists LIN28B status, age, sex, tumor site, tumor staging, treatment status, EwS-FLI1 translocation details of EwS1-4 samples. Primary
EwS spheres were cultured in IMDM (GIBCO), supplemented with 20% KO serum (GIBCO), 10ng/mL human recombinant EGF and
bFGF (PROSPEC), and 1% Pen/Strep (GIBCO) in ultra-low attachment flasks (Corning), as previously described (Suva` et al., 2009).
HpMSCswere obtained frombonemarrow of two healthy pediatric patients undergoing corrective surgery as described previously
(Riggi et al., 2008). Both HpMSC1 and HhMSC2 were obtained from male patients. HpMSCs were cultured at low confluence in
IMDM (GIBCO), 10% FCS (PAN BIOTECH), 10ng/mL PDGF-BB (PeproTech), and 1% Pen/Strep (GIBCO), and were tested for multi-
lineage differentiation into adipocytes, chondrocytes, and osteoblasts (Riggi et al., 2008).
The Lenti-X 293T cell line was purchased fromClontech (cat no. 632180) and grown in DMEMmedium (GIBCO) supplemented with
10%FCS (PANBIOTECH) and 1%Pen/Strep (GIBCO). The A673 cell line was purchased fromATCC (cat no. CRL-1598) and grown in
RPMI (GIBCO) supplemented with 10% FCS (PAN BIOTECH) and 1% Pen/Strep (GIBCO).
Cell cultures were maintained at 37C and 5% CO2 in humidified culture incubators.
Animal Studies
Experimental protocols involving mice were approved by the Veterinary Service of the Canton of Vaud, Switzerland (Etat de Vaud,
Service Ve´te´rinaire) under the authorization number VD2488. NOD-scid IL2Rgammanull mice (NSG) purchased from The Jackson
Laboratory, USA (stock number 005557) were used in this study. All mice were 6-8 weeks old males. Mice weremaintained in a path-
ogen-free environment in individual ventilated cages and fed with autoclaved food and water at the animal Facility of the University of
Lausanne.
METHOD DETAILS
Plasmids and Lentiviral Infection
Stable LIN28B depletion was obtained using either pLKO.1 lentiviral shRNA vectors purchased from the RNAi Consortium (shRNA
n.1 ref. TRCN0000219859; shRNA n.2 ref. TRCN0000122191), or a previously described sgRNA targeting LIN28B exon 2 (Powers
et al., 2016) cloned into the lentiCRISPRv2 vector. Control cells were infected with shRNA and sgRNA sequences targeting the
GFP transcripts (GCAAGCTGACCCTGAAGTTCAT). The shRNA sequence used for EWS-FLI1 depletion was previously described
and validated (Tirode et al., 2007). For LIN28B overexpression, the LIN28B cDNA was amplified from A673 cells and cloned into
the pLIV lentiviral vector. Lentiviruses were produced using Lenti-X 293T packaging cells, transfected with the plasmid of interest,
GAG/POL and VSV using FuGene 6 (Promega). In all cases, EwS cell suspensions from dissociated spheres were subject to lentiviral
infection for 8hrs in the presence of 6mg/mL Polybrene (Sigma-Aldrich), and cells were selected with 1mg/mL puromycin (InvivoGen)
for 48hrs prior to further analysis, as previously described (De Vito et al., 2012). HpMSCs infected with the pInd EWS-FLI1 V5 lentiviral
vector (Boulay et al., 2017) were selected with 1500mg/mL geneticin (ThermoFisher Scientific) for 8 days and then treated with 1 mg/
mL doxycycline (Sigma-Aldrich) for 8 supplementary days with medium renewal every other day.
RNA In Situ Hybridization, Immunohistochemistry and Western Blot Analyses
RNAscope technology (Advanced Cell Diagnostics, ACD) was used for RNA in situ hybridization following themanufacturer’s instruc-
tions as described previously (Filbin et al., 2018). Briefly, slides were baked for 1hr at 60C, deparaffinized and dehydrated. The tissue
was pretreated with Hydrogen Peroxide for 10 minutes at room temperature and with Target Retrieval Reagent for 15 minutes at
98C. Protease Plus was then applied for 30minutes at 40C. LIN28B probe (ACD) was hybridized for 2hrs at 40C, followed by signal
amplification. Tissue was counterstained with Gill’s hematoxylin followed by mounting with VectaMount mounting media (Vector
Laboratories).
For immunohistochemistry (IHC) EwS spheres were re-suspended in 1.5% low-melting agarose and included in paraffin blocks.
The blocks were sectioned and stained using LIN28B-specific polyclonal antibody (Proteintech). The signal was revealed using
goat anti-rabbit Ig conjugated to HRP (Sigma-Aldrich).e3 Cell Reports 30, 4567–4583.e1–e5, March 31, 2020
Western blots were analyzed according to standard procedures. The antibodies used were: rabbit polyclonal anti-human LIN28B
antibody (Cell Signaling Technology), mouse monoclonal anti-GAPDH peroxidase conjugated antibody (Sigma-Aldrich), mouse
monoclonal anti-a-tubulin antibody (Millipore), rabbit polyclonal anti-FLI1 antibody (Abcam), rabbit polyclonal anti-EWS antibody
(Bethyl Laboratories).
RNA Isolation and Real-Time qPCR
Total RNA was isolated using miRCURY RNA Isolation Kit – Cell & Plant (Exiqon) according to the manufacturer’s recommendations.
Real-time qPCR was performed as previously described (Riggi et al., 2010) using PowerUp SYBR Green (Applied Biosystems).
Primer sequences used for gene expression are listed in Table S5. Relative gene expression levels were calculated with the DDCt
method after normalization of the Ct values to the geometric mean of the Ct values of three housekeeping genes (GAPDH, 36B4
and TBP). SYBR Green primers for miRNA immature forms were previously published (Jiang et al., 2005). For miRNA mature form
expression quantification, RT-qPCR was performed as previously described (Cornaz-Buros et al., 2014).
Cell vitality, proliferation assays and drug tests
For cell viability assays, freshly dissociated spheres were stained with 1mg/mL Calcein AM cell-permeable-dye (ThermoFisher
Scientific) and analyzed by FACS. For clonogenic assays Calcein-positive single cells were FACS-sorted onto ultra-low attachment
96-well plates (Corning) and cultured in complete KO medium for 15 days, when sphere formation was assessed. Cell proliferation
was determined by MTS assays (CellTiter 96, Promega), according to the manufacturer’s recommendations.
For pharmacological targeting of LIN28B, the 1632 chemical inhibitor (Tocris) was dissolved in DMSO (Sigma-Aldrich) according to
the manufacturer’s recommendations. EwS spheres were dissociated and re-suspended in 6-well plates (Corning) in complete me-
dium containing either solvent (DMSO) or the 1632 inhibitor at day 0. The drug was added at a concentration of 50 or 250mM, and an
equal volume of DMSOwithout the drug was used as a control. Media were aspirated on day 4 and replaced with fresh medium con-
taining DMSO or the inhibitor.
For clonogenic assays, spheres were pre-treated with DMSO or the 1632 inhibitor for 4 days, then resuspended, stained with 1mg/
mL Calcein AM cell-permeable-dye (ThermoFisher Scientific) and single Calcein-positive cells were FACS-sorted onto ultra-low
attachment 96-well plates (Corning) containingmediumwith DMSOor the 1632 inhibitor. Media were removed on day 7 and replaced
with fresh medium containing DMSO or the inhibitor. For in vivo tumorigenicity assays, EwS spheres were pre-treated in culture for
4 days with DMSO or the inhibitor prior to injection.
For the analysis of EWS-FLI1 RNA stability, EwS2 cells were treated with 10mg/mL of ActD (Sigma-Aldrich), or an equal volume of
solvent (DMSO) as control. Cells were infected with shCTRL or sh2 LIN28B lentiviral vectors. ActD or DMSO were added 36hrs later,
and RNA was harvested at 0, 4, 8, 12 and 24hrs post-ActD treatment. Relative gene expression levels were calculated by real-time
qPCR using DDCt method normalized to GAPDH expression levels.
Nascent RNA capture and cDNA synthesis
Nascent RNA capture was performed with a Click-iT Nascent RNA Capture Kit (Life Technologies) according to the manufacturer’s
instructions. Briefly, cells were incubated with 5-EU at a concentration of 0.5mM for 30 minutes. Total RNA was isolated using Nu-
cleoSpin miRNA kit (Macherey-Nagel) and biotinylated. Following RNA precipitation, Dynabeads provided in the kit were used to
isolate the nascent RNA with incorporated 5-EU. For cDNA synthesis from the bound nascent RNA, the bead suspension was
warmed at 70C for 5 minutes. Random primers (Promega) and dNTP (MP Biomedicals) were immediately added to the mixture.
The suspension was left to cool down to room temperature for 30 minutes under constant rotation. M-MLV Reverse Transcriptase
(Promega) and RNasin Ribonuclease inhibitor (Promega) were subsequently added to the suspension, which was then warmed to
42C for 1hr with gentle vortexing. Finally, the cDNA was collected after heating the solution for 5 minutes at 85C.
In vivo tumorigenicity assays
For kidney subcapsular injections mice were anesthetized using 100mg/kg Ketamine (Ketasol-100, Graueb AG) and 16mg/kg Xyla-
zine (Rompun 2%, Provet AG) dissolved in PBS and 1x104 sphere-derived cells were injected beneath the renal capsule. Tumor
growth was monitored weekly using ultrasound imaging (Vevo 2100 Ultrasound Device, 40-MHz probe, VisualSonics, Canada). Tu-
mor volume was calculated by the following formula: V = 4/3 p 3 (Dd 3 Ds 3 Dt)/8, where Dd corresponds to tumor height, and Ds
and Dt to tumor lengths measured in long- and short-axis views, respectively. For the experiment in Figure 2, mice were sacrificed
when tumors reached 1cm3. For the experiments in Figures 3 and 6, mice were sacrificed when control tumors reached 1cm3. For the
experiment in Figure 5, mice where sacrificed 8 weeks after injection. Harvested tumors were further processed for RNA extraction,
hematoxylin/eosin staining, and IHC.
RNA Immunoprecipitation
RNA immunoprecipitation (RIP) on total EwS1 and EwS2 cell lysates was conducted using the EZ-Magna RIPTMRNA-Binding Protein
Immunoprecipitation kit (MerckMillipore), according to the manufacturer’s instructions. Rabbit polyclonal anti-human LIN28B anti-
body (Cell Signaling Technology) was diluted 1:50, as recommended by the manufacturer. Briefly, following gentle lysis of the cells
at80C, total lysates were incubated overnight with anti-LIN28B antibody pre-bound to magnetic beads provided with the kit. TheCell Reports 30, 4567–4583.e1–e5, March 31, 2020 e4
beads were then rinsed and the antibody-protein-RNA complexes were dissociated by proteinase K digestion for 30 minutes. RNA
was purified using the miRCURY RNA Isolation Kit - Cell & Plant (Exiqon) and enrichment of the selected LIN28B-bound transcripts
was assessed by RT-qPCR. Ct values obtained for the genes of interest were normalized to Ct values obtained from 10% of the input
(corresponding to the non-immunoprecipitated RNA obtained from the same sample).
Achilles scores and survival analysis
ATARIS scores were obtained from the project Achilles CRISPR screening data (Aguirre et al., 2016). The median ATARIS score for
each gene was used to select the top 100 genes associated with the strongest reduction in EwS cells growth. To determine the cor-
relation between the expression of these genes and survival in Ewing sarcomawe used the results of (Savola et al., 2011), available as
GSE17618. Cox univariate analysis in the R computing environment (R Development Core Team, 2019, https://www.R-project.org)
was used to determine the correlation between the expression of each gene and event-free survival.
LIN28B expression in an Ewing sarcoma dataset
We retrieved the gene-level normalized data of 65 primary Ewing tumors (Brohl et al., 2014) from Oncogenomicsdb and represented
expression as log2(RPKM+1). Microarray data were retrieved as normalized expression levels from the respective GEO records
(GSE17618; GSE34620; GSE12102). As the detection threshold, we used the median expression over all genes and samples. Cor-
relation between gene expression and survival was evaluated by Cox univariate analysis on logarithmic expression values using
event-free survival times. To assess possible associations between LIN28B status and somatic mutations in known oncogenes,
we used Fisher exact test to determine whether tumors expressing LIN28B were significantly overrepresented among those carrying
somatic mutations in STAG2, CKDN2A, TP53, or BRCA2, as reported in Table S5 of Brohl et al. (2014).
Analysis of RNA-seq data
Gene-level counts were obtained by aligning reads to the human transcriptome (Ensembl version 79 (Aken et al., 2017)) using RSEM
(Li and Dewey, 2011). When comparing LIN28B-positive versus negative spheres we considered as differentially expressed the
genes with absolute log2 fold-change greater than one in all four possible comparisons. For the shRNA and 1632 compound exper-
iments, we considered as differentially expressed between two conditions the genes with log2(TPM+1) greater than 3 in at least one
of the conditions and absolute log2 fold-change between the two conditions greater than one. The condition log2(TPM+1) in at least
one of our samples was also used to select the genes used in analyzing the overlap between our differentially expressed genes and
gene lists derived from external databases.
MicroRNA expression analysis
We used the Affymetrix miRNA 4.0 platform to compare miRNA expression between two LIN28B+ and two LIN28B– tumors. RMA
normalization and background subtraction were performed using the ‘‘oligo’’ Bioconductor package (Carvalho and Irizarry, 2010).
Differential expression was evaluated using the ‘‘limma’’ Bioconductor package (Ritchie et al., 2015) and miRNAs with absolute
log2 of fold change greater than 1 and nominal p < 0.01 were considered differentially expressed. Their expression z-score are shown
in the heatmap of Figure 5A, together with the p value of the enrichment of their targets among genes that were found differentially
expressed in LIN28B-positive versus negative spheres. Specifically, we evaluated, by exact Fisher test, the overlap between pre-
dicted targets of up- (down-) regulated miRNAs (obtained from TargetScan [Agarwal et al., 2015] and genes that are down- (up-)
regulated in LIN28B+ spheres. The size of the overlap and the corresponding p values are shown beside the heatmap.
Overlap between differentially expressed genes and gene sets
The overlap between lists of differentially expressed genes and gene sets shown in the Venn diagrams was evaluated for statistical
significance using exact Fisher test. The ‘‘chemical and genetic perturbations’’ gene sets of the Broad Institute MSIGDB database
were obtained from their website. The heatmaps represent the expression z-score of the common genes in the conditions indicated.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis of wet lab experiments (Student’s t test, 2-way ANOVA, Kaplan-Meyer test, Fisher’s exact test) were performed by
Prism GraphPad Software 8.00. All statistical tests and sample numbers are disclosed in respective Figure Legends/Supplementary
Tables.
Statistical analysis of bioinformatics data are described in details in the ‘‘Method Details’’ section.
DATA AND CODE AVAILABILITY
Gene expression data generated for this project are available for the Gene Expression Omnibus repository under accession
GSE122632 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122632). All the software used in the analysis and the
data generated for other publications are publicly available as detailed in the Key Resources Table.e5 Cell Reports 30, 4567–4583.e1–e5, March 31, 2020
